TNFRSF17 and Miyoshi myopathy: Separately, cellular chimeric antigen receptor T cell (CAR‐T) therapy (CAR‐T) and antibody‐drug conjugate (ADC)‐based agents targeting B‐cell maturation antigen (BCMA) have shown activity in heavily pretreated MM [7].